Investigational drug · Phase 3
Purinostat Mesylate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Purinostat Mesylate"
First trial start
2024
Mar 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Purinostat Mesylate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Recurrent and Refractory Diffuse Large B-cell Lymphoma
Approved drugs for the same conditions: Multiple myeloma · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Purinostat Mesylate" as an intervention, largest first.
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07011056 · 390 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 30, 2029
Drug: Purinostat Mesylate for Injection; Selinexor Tablets · For: Recurrent and Refractory Diffuse Large B-cell Lymphoma
Sites: Chengdu, China
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06484829 · 144 participants (planned) · Start Mar 25, 2024 · Primary completion Feb 1, 2026
Drug: Purinostat Mesylate 4 mg/m2; Purinostat Mesylate 6 mg/m2 and 1 more · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Chengdu, China
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06431243 · 132 participants (planned) · Start May 8, 2024 · Primary completion May 1, 2026
Drug: A0/B0 group Purinostat Mesylate 11.2mg/m2; A0/B0 group Purinostat Mesylate 15mg/m2 and 8 more · For: Advanced Solid Tumor
Sites: Guanzhou, China; Chengdu, China
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Active, not recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT05563844 · 74 participants · Start Nov 8, 2022 · Primary completion Dec 30, 2026
Drug: PM 8.4 mg/m^2; PM 11.2 mg/m^2 · For: Diffuse Large B Cell Lymphoma,DLBCL
Sites: Shanghai, China; Chengdu, China
- A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaActive, not recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06485219 · 50 participants (planned) · Start Apr 14, 2024 · Primary completion Jun 30, 2026
Drug: 11.2 mg/m2 Purinostat Mesylate; 15 mg/m2 Purinostat Mesylate · For: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL)
Sites: Shanghai, China; Chengdu, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT05526313 · 29 participants · Start Aug 10, 2020 · Primary completion Sep 7, 2022
Drug: Purinostat Mesylate 1.2mg/m^2; Purinostat Mesylate 2.4mg/m^2 and 5 more · For: Diffuse Large B Cell Lymphoma,DLBCL
Sites: Chengdu, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07809217 · 6 participants (planned) · Start Nov 9, 2026 · Primary completion Dec 15, 2026
Drug: 19 mg /50 μCi of [¹⁴C] Purinostat Mesylate · For: MB
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Distribution, metabolism, and excretion of [14C] purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in rats analyzed by high-performance liquid chromatography coupled with LTQ orbitrap mass spectrometry/radioactivity monitoring.
Ma Z, Tang M, Yang L, et al. · J Pharm Biomed Anal 2025
- Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
Yang L, Qiu Q, Wang J, et al. · Signal Transduct Target Ther 2025
- HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells.
Qiu Q, Yang L, Feng Y, et al. · Bioact Mater 2023
- Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model.
Zhu Z, Wen J, Xu Y, et al. · Ann Med 2022
- [In vitro pharmacodynamic studies of novel class ࡰ and ࡱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
Wang J, Zhao AL, Li H, et al. · Zhonghua Xue Ye Xue Za Zhi 2022
- Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia.
Yang L, Qiu Q, Tang M, et al. · Clin Cancer Res 2019
Also in development for Relapsed or Refractory Multiple Myeloma (RRMM)
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
- YKST02Phase 21 trial
Excyte Biopharma Ltd · Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.